Recruiting Heart Failure Studies in Fairhope
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, a...
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study...
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This study will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascu...
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function...
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive tr...
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure....
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (ina...
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF....
About Heart Failure Clinical Trials in Fairhope
Heart failure is a chronic condition where the heart cannot pump blood efficiently to meet the body's needs. It affects millions of people worldwide and can result from various heart conditions. Treatment includes medications, lifestyle changes, devices, and in severe cases, heart transplant.
There are currently 8 heart failure clinical trials recruiting participants in Fairhope, ALABAMA. These studies are seeking a combined 31,596 participants. Research is being sponsored by AstraZeneca, Novo Nordisk A/S, Amgen and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Heart Failure Clinical Trials in Fairhope — FAQ
Are there heart failure clinical trials in Fairhope?
Yes, there are 8 heart failure clinical trials currently recruiting in Fairhope, ALABAMA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Fairhope?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Fairhope research site will contact you about next steps.
Are clinical trials in Fairhope free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Fairhope studies also compensate for your time and travel.
What heart failure treatments are being tested?
The 8 active trials in Fairhope are testing new therapies including novel drugs, biologics, and treatment approaches for heart failure.
Data updated March 2, 2026 from ClinicalTrials.gov